Skip to content
Screener

NewAmsterdam Pharma Company NAMS Cash & Equivalents

Cash & Equivalents at other companies

Merck & Co. logo
Merck & Co.MRK
$6.89B-14.6%
Amgen logo
AmgenAMGN
$574M+5.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.47B+22.3%
RFL
Rafael Holdings, Inc.RFL
$30.5M-19.6%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$204.64M+41.8%
Arvinas logo
ArvinasARVN
$87.3M+7.8%

Other financials

Income statement

See full
Revenue$3.7M-80.7%
Operating income-$64.9M-82.0%
Net income-$64.1M-269%
EPS (diluted)-$0.52-247%

Balance sheet

See full
Total debt$82.0K-75.0%
Total equity$631.4M-18.9%
Total assets$704.5M-13.6%

Cash flow

See full
Operating cash flow-$39.2M-4.1%
CapEx$80.0K-9.1%
Free cash flow-$39.3M-4.1%

Valuation

See full
Market cap$3.31B+24.7%
Enterprise value$2.88B+38.1%
P/S464.5×+423×

Profitability

See full
Operating margin-3,432.2%-3,753pp
Net margin-3,644.2%-3,946pp
FCF margin-2,018.3%-2,259pp

Returns & leverage

See full
Return on equity-36.8%+15.4pp
Debt / equity0×0.0×
Current ratio9×-12.1×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333824
Line itemJune 30,2026December 31,2025
(In thousands of USD)
Assets
Current assets:
Cash and cash equivalents424,151490,002
Prepayments and other receivables23,99638,138
Marketable securities, current209,703146,239
Restricted cash1,3571,321
Total current assets659,207675,700

Item 1. Financial Statements.

FAQ

What is NewAmsterdam Pharma Company's cash & equivalents?
NewAmsterdam Pharma Company (NAMS) reported cash & equivalents of $424.15M in Q2 2026.
How has NewAmsterdam Pharma Company's cash & equivalents changed year-over-year?
NewAmsterdam Pharma Company's cash & equivalents decreased by 24.8% year-over-year, from $563.86M to $424.15M.
What is the long-term trend for NewAmsterdam Pharma Company's cash & equivalents?
Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's cash & equivalents has grown at a 1.6% compound annual growth rate (CAGR), from $467.73M to $490M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about NewAmsterdam Pharma Company's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude